These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15609005)

  • 41. [Dendrite cell-based cancer vaccines--clinical application].
    Svane IM; Berntsen A; Trepiakas R; Pedersen AE
    Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.
    Huang FP; Chen YX; To CK
    Eur J Immunol; 2011 Jan; 41(1):18-25. PubMed ID: 21182072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
    Fecek RJ; Storkus WJ
    Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
    Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
    Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer.
    Lin CM; Wang FH; Lee PK
    Clin Immunol; 2002 Jan; 102(1):96-105. PubMed ID: 11781072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trials with tumor antigen genetically modified dendritic cells.
    Ribas A
    Semin Oncol; 2005 Dec; 32(6):556-62. PubMed ID: 16338421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity.
    Wells JW; Cowled CJ; Darling D; Guinn BA; Farzaneh F; Noble A; Galea-Lauri J
    Cancer Immunol Immunother; 2007 Dec; 56(12):1861-73. PubMed ID: 17487489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
    Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
    Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The immunogenicity of dendritic cell-derived exosomes.
    Quah BJ; O'Neill HC
    Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of dendritic cell therapy for cancer: progress and challenges.
    Mantia-Smaldone GM; Chu CS
    BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
    Rossowska J; Pajtasz-Piasecka E
    Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
    Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
    Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review: the application of dendritic cell-derived exosomes in tumour immunotherapy.
    Quah B; O'Neill HC
    Cancer Biother Radiopharm; 2000 Apr; 15(2):185-94. PubMed ID: 10803324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.
    Park MY; Kim HS; Woo SJ; Kim CH; Park JS; Sohn HJ; Kim HJ; Oh ST; Kim TG
    Eur J Immunol; 2008 Aug; 38(8):2106-17. PubMed ID: 18624349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.